Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers

As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration. View full story: https://www.biocentury.com/article/658829 ...